1185427-23-9

Basic information

• Product Name: 3-(4,4,5,5-TetraMethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-pyrrolo[2,3-c]pyridine
• Synonyms: 3-(4,4,5,5-TetraMethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-pyrrolo[2,3-c]pyridine;1-Tosyl-1H-pyrrolo[2,3-c]pyridine-3-boronic acid pinacol ester
• CAS NO: 1185427-23-9
• Molecular Formula: C20H23BN2O4S
• Molecular Weight: 398.28362
• Mol File: 1185427-23-9.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(4,4,5,5-TetraMethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-pyrrolo[2,3-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4,4,5,5-TetraMethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-pyrrolo[2,3-c]pyridine(1185427-23-9)
• EPA Substance Registry System: 3-(4,4,5,5-TetraMethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-pyrrolo[2,3-c]pyridine(1185427-23-9)

Safety Data

• Hazardous Substances Data: 1185427-23-9(Hazardous Substances Data)

Usage

Structure

Contains a unique boron-containing ring structure derived from pyrrolopyridine and tosyl, with a dioxaborolane moiety

Potential applications

Medicinal chemistry, drug development, building block for synthesis of pharmaceutical compounds, ligand in catalytic processes

Relevance

Unique structure and reactivity make it potentially valuable in various chemical processes and applications

Importance

Further research and characterization may uncover additional properties and applications for this compound.

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 1185427-21-7 3-bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-c]pyridine 
• 73183-34-3 bis(pinacol)diborane 
• 1449115-33-6 1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-c]pyridine 
• 271-29-4 6-azaindole 

Relevant articles and documents

Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors

Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) regulates the proliferation and differentiation of neuronal progenitor cells during brain development. Consequently, DYRK1A has attracted interest as a target for the treatment of neurodegenerative diseases, including Alzheimer's disease (AD) and Down's syndrome. Recently, the inhibition of DYRK1A has been investigated as a potential treatment for diabetes, while DYRK1A's role as a mediator in the cell cycle has garnered interest in oncologic indications. Structure-activity relationship (SAR) analysis in combination with high-resolution X-ray crystallography leads to a series of pyrazolo[1,5-b]pyridazine inhibitors with excellent ligand efficiencies, good physicochemical properties, and a high degree of selectivity over the kinome. Compound 11 exhibited good permeability and cellular activity without P-glycoprotein liability, extending the utility of 11 in an in vivo setting. These pyrazolo[1,5-b]pyridazines are a viable lead series in the discovery of new therapies for the treatment of diseases linked to DYRK1A function.